Curcumin's potential anxiolytic and antidepressant impacts do not significantly alter behavior or interact with the benzodiazepine site of the gamma-aminobutyric acid receptor A.
In this study, a prospective, between-subjects group design was employed. The subjects were 55 male Sprague-Dawley rats randomly split into five groups, each given different intraperitoneal injections: a control group, curcumin, curcumin with flumazenil, midazolam alone, and midazolam with curcumin. Behavioral observations were conducted with the aid of the elevated plus maze, open field test, and forced swim tests. A two-tail multivariate analysis of variance was deployed for data analysis.
The results showed that, according to the behavioral tests, curcumin did not generate any notable signs of anxiety-relieving or mood-lifting effects. It was also noticed that curcumin didn't show any interactive tendencies with the GABAA receptor's benzodiazepine site. The team therefore concluded that curcumin didn't produce any significant outcomes on these aspects of mental health modulation as was purposed in the initial hypothesis.
